Soon after FDA approved a novel device to treat opioid use disorder, FDA approved the first and only once-monthly injectable buprenorphine formulation to treat moderate to severe opioid use disorder (OUD).
Soon after FDA approved a novel device to treat opioid use disorder, FDA approved the first and only once-monthly injectable buprenorphine formulation to treat moderate to severe opioid use disorder (OUD).
FDA granted the approval of buprenorphine extended-release injection for subcutaneous use (CIII) (Sublocade) to Indivior PLC.
Related: FDA clears first opioid withdrawal device
In mid-November, FDA also granted a new indication to the NSS-2 Bridge device (Innovative Health Solutions), a small electrical nerve stimulator placed behind the patient’s ear, which can help reduce the symptoms of withdrawal from the prescription pain drugs.
Meanwhile, Sublocade-available to patients in the US in the first quarter of 2018-is intended to be administered only by healthcare providers and should be used as part of a complete treatment program that includes counseling and psychosocial support, according to Indivior.
Related: Activists: drugmakers, distributors liable for opioids abuse
Sublocade is the first and only therapy that, at steady state, delivers buprenorphine at a sustained rate of at least 2 ng/mL over a one-month period, Shaun Thaxter, CEO of Indivior, said in a statement.
“Sublocade is a scientific innovation that represents a new treatment option to help patients attain more illicit opioid-free weeks during their treatment program,” Thaxter said. “The urgency for this new treatment has never been greater, as the U.S. opioid crisis has been declared a national public health emergency.”
In the Opioid Blockade Study, Sublocade achieved complete blockade of drug-liking effects for a full month in most patients. In a 12-week trial evaluating the blocking effect, Sublocade 300 mg fully blocked the drug-liking effects of hydromorphone.
Healthcare settings and pharmacies that order and dispense Sublocade must be certified in the Sublocade REMS Program.
Read more: FDA advisors recommend 2 opioid use disorder drugs
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.